Why Arteris Stock Is Back In Focus After Q2 Results
Arteris (AIP) moved back onto investor watchlists after second quarter 2026 earnings showed higher revenue alongside a wider net loss, and a same day announcement of a new Chief Financial Officer.
See our latest analysis for Arteris.
Over the past year Arteris has moved sharply higher, with a year to date share price return of 102.95% and a 1 year total shareholder return of 239.63%. This suggests momentum has been building even as quarterly losses and the CFO transition reshape the risk profile.
If Arteris has you looking more closely at chip and AI infrastructure suppliers, this is a good moment to scan the wider opportunity set using the 55 AI infrastructure stocks
Arteris now trades at a clear discount to both analyst targets and an estimated fair value, even after the strong run and widening losses. Is that a sign of excessive caution or a reasonable response to the risks ahead?
Most Popular Narrative: 16.2% Undervalued
Arteris closed at $31.62, while the most followed narrative pegs fair value at $37.75, which frames the recent Q2 reaction against a richer long term story.
The ongoing industry transition to chiplet based and heterogeneous integration architectures is expanding Arteris' addressable market, with chiplet related design starts expected to rise from 5% to 30% in coming years. This structural trend supports both higher sales volume and increased average selling prices, benefiting future top line revenue.
Want to see why this narrative stretches fair value above today’s price? It hinges on rapid revenue expansion, margin repair, and a future earnings multiple usually reserved for market leaders. Curious which exact growth and profitability assumptions have to line up to support that outcome? The full narrative lays out the numbers and timing in detail.
Result: Fair Value of $37.75 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the bullish Arteris narrative still depends on R&D spending translating into profitable growth, and on large customers not scaling back or replacing its IP over time.
Find out about the key risks to this Arteris narrative.
Another View On Arteris Valuation
The earlier narrative framed Arteris as 16.2% undervalued against a fair value of $37.75. The price to sales picture looks very different. Arteris trades on a P/S of 19x, compared with a 3.8x industry average, a 2.5x peer average, and a 6.8x fair ratio. Is the discount story really so straightforward?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Arteris attracting both optimism and caution, this is the moment to move quickly, review the full picture, and weigh the 3 key rewards and 3 important warning signs.
Looking For More Investment Ideas Beyond Arteris?
If Arteris has sharpened your focus, do not stop here. Broaden your watchlist now so you are not relying on a single story for future decisions.
- Target higher potential upside by scanning 20 elite penny stocks with strong financials that already back their share price with solid financials and real operating progress.
- Spot opportunities that combine quality with pricing appeal by reviewing the 49 high quality undervalued stocks, which filters for strong cash flows and robust balance sheets.
- Prioritise resilience and sleep easier at night by checking the 78 resilient stocks with low risk scores that highlights companies with lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com